Title
Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air<sup>®</sup> App
Date Issued
01 July 2020
Access level
open access
Resource Type
journal article
Author(s)
Bédard A.
Antó J.M.
Fonseca J.A.
Arnavielhe S.
Bachert C.
Bedbrook A.
Bindslev-Jensen C.
Bosnic-Anticevich S.
Cardona V.
Cruz A.A.
Fokkens W.J.
Garcia-Aymerich J.
Hellings P.W.
Ivancevich J.C.
Klimek L.
Kuna P.
Kvedariene V.
Larenas-Linnemann D.
Melén E.
Monti R.
Mösges R.
Mullol J.
Papadopoulos N.G.
Pham-Thi N.
Samolinski B.
Tomazic P.V.
Toppila-Salmi S.
Ventura M.T.
Yorgancioglu A.
Bousquet J.
Pfaar O.
Basagaña X.
Aberer W.
Agache I.
Akdis C.A.
Akdis M.
Aliberti M.R.
Almeida R.
Amat F.
Angles R.
Annesi-Maesano I.
Ansotegui I.J.
Arnavielle S.
Asayag E.
Asarnoj A.
Arshad H.
Avolio F.
Bacci E.
Baiardini I.
Barbara C.
Barbagallo M.
Baroni I.
Barreto B.A.
Bateman E.D.
Bedolla-Barajas M.
Bewick M.
Beghé B.
Bel E.H.
Bergmann K.C.
Bennoor K.S.
Benson M.
Bertorello L.
Białoszewski A.Z.
Bieber T.
Bialek S.
Bjermer L.
Blain H.
Blasi F.
Blua A.
Bochenska Marciniak M.
Bogus-Buczynska I.
Boner A.L.
Bonini M.
Bonini S.
Bosse I.
Bouchard J.
Boulet L.P.
Bourret R.
Bousquet P.J.
Braido F.
Briedis V.
Brightling C.E.
Brozek J.
Bucca C.
Buhl R.
Buonaiuto R.
Panaitescu C.
Burguete Cabañas M.T.
Burte E.
Bush A.
Caballero-Fonseca F.
Caillaud D.
Caimmi D.
Calderon M.A.
Camargos P.A.M.
Camuzat T.
Canfora G.
Canonica G.W.
Carlsen K.H.
Carreiro-Martins P.
Publisher(s)
John Wiley and Sons Inc
Abstract
Background: In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently. Methods: All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom-medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra-individual response variability (IRV) index was calculated. Results: A strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures. Conclusions: VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom-medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies.
Start page
1672
End page
1688
Volume
75
Issue
7
Language
English
OCDE Knowledge area
Ingeniería de sistemas y comunicaciones
Epidemiología
Psicología
Subjects
Scopus EID
2-s2.0-85081893884
PubMed ID
Source
Allergy: European Journal of Allergy and Clinical Immunology
ISSN of the container
01054538
DOI of the container
10.1111/all.14204
Source funding
Novartis
Florida Agricultural Experiment Station
UCB
AstraZeneca
Teva Pharmaceutical Industries
Meso Scale Diagnostics
GlaxoSmithKline
Mylan
MEDA
Sponsor(s)
Dr Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, outside the submitted work. Dr Bosnic‐Anticevich reports grants from TEVA, personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan, outside the submitted work. Dr Cardona reports personal fees from ALK, Allergopharma, Allergy Therapeutics, Diater, LETI, Thermofisher, Stallergenes, outside the submitted work. Dr Fonseca being a partner in a company developing mobile technologies for monitoring airways diseases. Dr Hellings reports grants and personal fees from Mylan, during the conduct of the study; personal fees from Sanofi, Allergopharma, Stallergenes, outside the submitted work. Dr Ivancevich reports personal fees from Faes Farma, Eurofarma Argentina, other from Sanofi, Laboratorios Casasco, personal fees from, outside the submitted work. Dr Kuna reports personal fees from Adamed, AstraZeneca, Boehringer Ingelheim, Hal, Chiesi, Novartis, Berlin Chemie Menarini, outside the submitted work. Dr Kvedariene reports personal fees from GSK, non‐financial support from StallergenGreer, Mylan, AstraZeneca, Dimuna, Norameda, outside the submitted work. Dr Larenas Linnemann reports personal fees from Amstrong, Astrazeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Grunenthal, GSK, MEDA, Menarini, MSD, Novartis, Pfizer, Novartis, Sanofi, Siegfried, UCB. grants from Sanofi, Astrazeneca, Novartis, UCB, GSK, TEVA, Boehringer Ingelheim, Chiesi.outside the submitted work. Dr MULLOL reports personal fees from SANOFI‐Genzyme‐Regeneron, ALK‐Abelló A/S, Menarini Group, MSD, GlaxoSmithKline, Novartis, GENENTECH ‐ Roche_Novartis, grants and personal fees from UCB Pharma, MYLAN‐MEDA Pharma, URIACH Group, outside the submitted work. Dr Papadopoulos reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, Boehringer Ingelheim, grants from Gerolymatos International SA, Capricare, outside the submitted work. Dr Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Purina, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, outside the submitted work. Dr Pfaar reports personal fees from MEDA Pharma/MYLAN, ASIT Biotech Tools SA Laboratorios LETI/LETI Pharma, Anergis S.A, Mobile Chamber Experts (a GALEN Partner), Indoor Biotechnologies, Astellas Pharma Global, grants and personal fees from ALK‐Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding BV/HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, grants from Biomay, Nuvo, Circassia, from, Glaxo Smith Kline, outside the submitted work. 2
Sources of information:
Directorio de Producción Científica
Scopus